Clinical Trial

Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

Study acronym: HyDEF
Recruiting
View on ClinicalTrials.gov →
Summary
This study evaluates the feasibility and safety of bridging radiation therapy, including a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) undergoing T-cell redirection therapies (CAR T-cell therapy or bispecific antibodies).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-03-25; most recent amendment 2026-06-17.
Status change: Not Yet Recruiting → Recruiting 2025-05-16
Trial Details
NCT Number NCT06898905
Lead Sponsor Yale University
Collaborators: American Cancer Society, Inc.
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 10 participants
Start Date 2025-10-30
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-22